Jean-Luc Breton

2.8k total citations
45 papers, 1.2k citations indexed

About

Jean-Luc Breton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Jean-Luc Breton has authored 45 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 10 papers in Epidemiology. Recurrent topics in Jean-Luc Breton's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (23 papers) and Cancer Treatment and Pharmacology (15 papers). Jean-Luc Breton is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (23 papers) and Cancer Treatment and Pharmacology (15 papers). Jean-Luc Breton collaborates with scholars based in France, Canada and United Kingdom. Jean-Luc Breton's co-authors include Élisabeth Quoix, D. Debieuvre, B. Milleron, A Depierre, É. Lemarié, Jean-Louis Pujol, Denis Moro‐Sibilot, Paul Rebattu, R. Gervais and G. Robinet and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

Jean-Luc Breton

41 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean-Luc Breton France 16 956 844 198 194 109 45 1.2k
Christopher W. Lee Canada 14 520 0.5× 448 0.5× 129 0.7× 326 1.7× 74 0.7× 24 980
Monika Serke Germany 15 688 0.7× 758 0.9× 129 0.7× 194 1.0× 46 0.4× 71 1.1k
R. Corre France 17 541 0.6× 816 1.0× 60 0.3× 84 0.4× 149 1.4× 88 1.0k
M. Veslemes Greece 16 788 0.8× 563 0.7× 197 1.0× 350 1.8× 17 0.2× 39 1.0k
M. Puglisi Italy 16 539 0.6× 408 0.5× 111 0.6× 257 1.3× 55 0.5× 38 998
Giuseppe Comella Italy 16 817 0.9× 642 0.8× 54 0.3× 163 0.8× 33 0.3× 42 1.1k
Pavlos Papakotoulas Greece 16 777 0.8× 426 0.5× 148 0.7× 144 0.7× 26 0.2× 52 1.0k
P Chomy France 10 1.3k 1.4× 1.0k 1.2× 547 2.8× 351 1.8× 56 0.5× 28 1.5k
L Portalone Italy 11 418 0.4× 427 0.5× 60 0.3× 156 0.8× 21 0.2× 26 668
Hamdy A. Azim Egypt 19 766 0.8× 352 0.4× 77 0.4× 230 1.2× 40 0.4× 66 1.1k

Countries citing papers authored by Jean-Luc Breton

Since Specialization
Citations

This map shows the geographic impact of Jean-Luc Breton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Luc Breton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Luc Breton more than expected).

Fields of papers citing papers by Jean-Luc Breton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Luc Breton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Luc Breton. The network helps show where Jean-Luc Breton may publish in the future.

Co-authorship network of co-authors of Jean-Luc Breton

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Luc Breton. A scholar is included among the top collaborators of Jean-Luc Breton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Luc Breton. Jean-Luc Breton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quoix, Élisabeth, I. Monnet, Philippe Scheid, et al.. (2010). IFCT 02-02 : la prise en charge du cancer bronchique chez les patients âgés de 70 ans et plus en France. Revue des Maladies Respiratoires. 27(5). 421–430. 22 indexed citations
2.
3.
Milleron, B., Élisabeth Quoix, V. Westeel, et al.. (2007). IFCT0002 phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy with two different CT regimens in resectable non-small cell lung cancer (NSCLC): Early results. Journal of Clinical Oncology. 25(18_suppl). 7519–7519. 2 indexed citations
4.
Cortot, Alexis B., L. Gérinière, G. Robinet, et al.. (2006). Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Annals of Oncology. 17(9). 1412–1417. 35 indexed citations
5.
Breton, Jean-Luc, David Braun, Élisabeth Quoix, et al.. (2006). Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: A multicenter phase II study. Lung Cancer. 51(3). 347–355. 4 indexed citations
6.
7.
Pujol, Jean-Louis, Jean-Luc Breton, R. Gervais, et al.. (2005). Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Annals of Oncology. 16(4). 602–610. 101 indexed citations
8.
Quoix, Élisabeth, Denis Moro‐Sibilot, M. Mercier, et al.. (2005). Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 97(7). 499–506. 105 indexed citations
9.
Bennouna, Jaafar, Ee Hong Tan, Mary O’Brien, et al.. (2004). Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. Journal of Clinical Oncology. 22(14_suppl). 7139–7139. 4 indexed citations
10.
Quoix, Élisabeth, Jean-Luc Breton, A Ducoloné, et al.. (2004). First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Lung Cancer. 47(3). 405–412. 15 indexed citations
11.
Gervais, R., A Ducoloné, Jean-Luc Breton, et al.. (2004). Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 16(1). 90–96. 104 indexed citations
12.
Quoix, Élisabeth, B Lebeau, A Depierre, et al.. (2003). Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy fornon-small-cell lung cancer. Annals of Oncology. 15(1). 38–44. 36 indexed citations
13.
Quoix, Élisabeth, Jean-Luc Breton, Casey L. Daniel, et al.. (2001). Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: A phase II study. Annals of Oncology. 12(7). 957–962. 38 indexed citations
14.
Quoix, Élisabeth, Jean-Luc Breton, Casey L. Daniel, et al.. (2000). Tolerability of a combination of carboplatin and etoposide phosphate in elderly patients with small cell lung cancer. A multicentric phase II clinical trial. Lung Cancer. 29(1). 41–41. 3 indexed citations
15.
16.
17.
Jacoulet, P., et al.. (1995). Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer. Lung Cancer. 12(3). 247–257. 12 indexed citations
18.
Depierre, A, B. Milleron, D Moro, et al.. (1995). 1053 Phase III study of neo-adjuvant chemotherapy in resectable non-small cell lung cancer (NSCLC). European Journal of Cancer. 31. S220–S220. 1 indexed citations
19.
Debieuvre, D., J.C. Dalphin, D. Pernet, et al.. (1991). Étude épidémiologique de la maladie du poumon de fermier et de la bronchite chronique chez 7509 agriculteurs fourragers du département du Doubs. La Revue de Médecine Interne. 12(3). S53–S53.
20.
Dalphin, J.‐C., et al.. (1988). Deux cas de paraffinose pulmonaire. La Revue de Médecine Interne. 9(4). 410–413. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher W. Lee Breakdown of academic impact, for papers by Monika Serke Breakdown of academic impact, for papers by R. Corre Breakdown of academic impact, for papers by M. Veslemes Breakdown of academic impact, for papers by M. Puglisi Breakdown of academic impact, for papers by Giuseppe Comella Breakdown of academic impact, for papers by Pavlos Papakotoulas Breakdown of academic impact, for papers by P Chomy Breakdown of academic impact, for papers by L Portalone Breakdown of academic impact, for papers by Hamdy A. Azim
Rankless by CCL
2026